Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors
AssigneeCorcept Therapeutics, Inc.
InventorJoseph K. Belanoff
Life of this patent
Estimating the term…
Loading patent…
AssigneeCorcept Therapeutics, Inc.
InventorJoseph K. Belanoff
Estimating the term…
Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor antagonist (GRA) and steroidogenesis inhibitors, and by concomitant administration of a GRA and CYP3A inhibitors. Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of mifepristone and ketoconazole. Subjects treated with CYP3A inhibitors or steroidogenesis inhibitors may suffer from toxicity or other serious adverse reactions; concomitant administration of other drugs would be expected to increase the risk of such toxicity and adverse reactions. Applicant has surprisingly found that GRAs may be administered to subjects receiving CYP3A inhibitors or steroidogenesis inhibitors such as ketoconazole without increasing risk adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole (a CYP3A inhibitor and a steroidogenesis inhibitor), providing safe concomitant administration of the GRA and ketoconazole. In embodiments, the GRA dose may be reduced.
A method of treating Cushing's syndrome in a patient who is taking a glucocorticoid receptor antagonist (GRA) comprising reducing the daily dose of said GRA from an original dose to an adjusted dose that is at least 25% less than said original dose when the patient is receiving concomitant administration of a CYP3A inhibitor.
A method of treating symptoms associated with elevated cortisol levels in a patient who is taking a glucocorticoid receptor antagonist (GRA) comprising reducing the daily dose of said GRA from an original dose to an adjusted dose that is at least 25% less than said original dose when the patient is receiving concomitant administration of a CYP3A inhibitor.
A method of controlling hyperglycemia secondary to hypercortisolism in a patient with endogenous Cushing's syndrome who is taking a glucocorticoid receptor antagonist (GRA) comprising reducing the daily dose of said GRA from an original dose to an adjusted dose that is at least 25% less than said original dose when the patient is receiving concomitant administration of a CYP3A inhibitor.
A method of controlling hyperglycemia secondary to hypercortisolism in a patient with endogenous Cushing's syndrome comprising administering a daily dose of mifepristone selected from 900 milligrams (mg) mifepristone, 600 mg mifepristone, and 300 mg mifepristone when the patient is receiving concomitant administration of a CYP3A inhibitor.
Dependencies are inferred from the claim text.